|
Phase III Success for Boehringer Ingelheim Asthma Drug
Genetic Engineering News Boehringer-Ingelheim said today its once-daily asthma drug tiotropium, delivered via Respimat® Soft Mist™ Inhaler, produced favorable Phase III results by increasing the time to first severe exacerbation, and time to first episode of asthma worsening … Boehringer Ingelheim's tiotropium shows promising results in patients with … Phase III results: tiotropium* Respimat® effective in symptomatic asthma … Boehringer Ingelheim reports positive data from symptomatic asthma trials |
View full post on asthma – Google News